Acute and Preventive Management of Episodic Migraine

Acute Treatment

• For mild episodic migraine attacks, use an NSAID (e.g., aspirin, ibuprofen, naproxen) or acetaminophen, alone or in combination, before escalating therapy. 1
• For moderate‑to‑severe attacks, the first‑line recommendation is a combination of a triptan (e.g., sumatriptan, rizatriptan, zolmitriptan) plus an NSAID or acetaminophen. 2
• Adequate dosing of NSAIDs/acetaminophen should be confirmed before adding a triptan or other agents. 3
• If the first‑line combination is ineffective or not tolerated, second‑line options include oral CGRP antagonists (gepants such as rimegepant, ubrogepant, zavegepant) or the ergot alkaloid dihydroergotamine. 4
• When second‑line agents fail, third‑line therapy with the ditan lasmiditan is recommended. 4
• In patients with severe nausea or vomiting, a non‑oral triptan formulation together with an anti‑emetic should be used. 2
• Opioids and butalbital‑containing products are expressly contraindicated for acute migraine treatment. 3
• Treatment should be initiated as early as possible after headache onset, preferably with the combination regimen, to maximize efficacy. 5

Preventive Treatment

• Initiate preventive therapy when any of the following apply:

  • Frequent episodic migraine attacks,
  • Inadequate response to acute therapy,
  • Intolerance or contraindications to acute medications, or
  • Use of acute medication on more days than guideline‑recommended limits.
    *These criteria are supported by multiple consensus statements. [1][4]6

• Preventive‑therapy principles:

  • Start at a low dose and titrate gradually to achieve desired reduction in migraine frequency.
  • Allow a trial period of 2–3 months before deeming a preventive agent ineffective.
  • Emphasize patient adherence, as clinical benefit typically emerges over several weeks.
  • Consider medication cost when selecting among agents with comparable efficacy. 6

• Alternative first‑line preventive agents for patients who cannot tolerate standard options include:

  • ACE inhibitor lisinopril,
  • ARBs candesartan or telmisartan,
  • SSRI fluoxetine. 6

Medication‑Overuse Headache (MOH)

• MOH is defined as headache occurring on ≥15 days per month for ≥3 months that is attributable to overuse of acute migraine medication. 1
• Overuse thresholds differ by drug class:
  
  • NSAIDs – use on ≥15 days/month,
  • Triptans – use on ≥10 days/month. 2

Pregnancy, Lactation, and Special Populations

• Clinicians should discuss potential adverse effects of all acute and preventive migraine medications with patients of child‑bearing potential. [5][6]

Lifestyle and Non‑Pharmacologic Measures

• Counsel patients to maintain adequate hydration, regular meals, consistent sleep, regular aerobic exercise, stress‑management techniques, weight control (if overweight/obese), and to identify and modify individual migraine triggers. 1
• Use a headache diary to track attack frequency, medication use, and response to therapy. 6

Cost Considerations

• When clinically appropriate, select the less‑expensive recommended medication to reduce overall treatment burden. [1][4]6

Annualized Wholesale Acquisition Costs (2025)

Costs derived from published pricing analyses. 4

Common Pitfalls

• Failing to ensure that NSAID/acetaminophen dosing is maximized before adding a triptan reduces treatment success. 2
• Assuming all agents within a drug class will have the same effect; patients may respond to one triptan but not another. 1
• Prescribing opioids or butalbital, which are contraindicated for migraine, increases risk of dependence and MOH. 3
• Not monitoring for MOH using the class‑specific overuse thresholds can lead to chronic daily headache. 1

Evidence‑Based Preventive Management of Episodic Migraine

Preventive Treatment Initiation

• Initiate preventive therapy in adults with episodic migraine (≈ 7–8 headache days/month, range 2–14) using a beta‑blocker (metoprolol or propranolol), an antiseizure medication (valproate), an SNRI (venlafaxine), or a tricyclic antidepressant (amitriptyline); if the first agent fails, proceed to a CGRP‑targeted oral gepant (atogepant or rimegepant) or a CGRP monoclonal antibody (eptinezumab, erenumab, fremanezumab, galcanezumab)【7】.

Guideline Priorities

• The American College of Physicians advises that, when efficacy is comparable, clinicians should prioritize lower‑cost options among preventive agents【7】.

First‑Line Preventive Agents (Cost‑Sensitive Selection)

• Beta‑blockers (metoprolol or propranolol) are recommended as a first‑line option【7】.
• Antiseizure medication (valproate) is recommended as a first‑line option【7】.
• SNRI (venlafaxine) is recommended as a first‑line option【7】.
• Tricyclic antidepressant (amitriptyline) is recommended as a first‑line option【7】.

Second‑Line Preventive Agents (CGRP‑Targeted Therapies)

• CGRP monoclonal antibodies—eptinezumab (intravenous, quarterly), erenumab, fremanezumab, or galcanezumab (subcutaneous, monthly or quarterly)—are recommended when first‑line agents are ineffective or not tolerated【7】.

Alternative First‑Line Options (When Standard Agents Are Not Tolerated)

• ACE inhibitor (lisinopril)【7】.
• Angiotensin‑II receptor blockers (candesartan or telmisartan)【7】.
• SSRI (fluoxetine)【7】.

Preventive Treatment Principles

• Begin at a low dose and titrate gradually to achieve the desired reduction in migraine frequency【7】.
• Allow a trial period of 2–3 months before deeming a preventive agent ineffective【7】.
• Emphasize medication adherence, as clinical benefit typically emerges over several weeks【7】.
• Switch to an alternative preventive medication if an adequate response is not achieved during the trial period or if adverse effects occur【7】.
• Consider medication cost as a key factor when selecting among agents with comparable efficacy【7】.

Lifestyle and Non‑Pharmacologic Measures

• Prior to pharmacologic therapy, assess and modify modifiable triggers; encourage adequate hydration, regular meals, consistent sleep, and regular aerobic exercise【7】.
• Behavioral interventions—cognitive‑behavioral therapy, relaxation training, and mindfulness‑based treatments—may reduce migraine frequency and improve migraine‑related disability【7】.
• Use a headache diary to track attack frequency, medication use, therapeutic response, and to identify possible medication overuse【7】.

Special Populations

• Discuss potential adverse effects of all acute and preventive migraine medications with patients of childbearing potential, including those who are pregnant or breastfeeding【7】.

Cost Considerations

• When clinically appropriate, select less expensive recommended medications to lessen the overall treatment burden【7】.
• Individual medication costs may vary according to insurance coverage and patient economic circumstances【7】.

Evidence level: not explicitly graded in the source; recommendations reflect expert consensus and cost‑effectiveness considerations.

Acute Migraine Management When Triptans Are Not Suitable

First‑Line Non‑Triptan Options

• NSAIDs (e.g., aspirin, ibuprofen, naproxen, diclofenac, celecoxib) are highly effective for moderate‑to‑severe migraine when used at appropriate doses – supported by high‑quality evidence. 8, 9
• Acetaminophen (≈1000 mg) is an effective alternative for patients who cannot take NSAIDs – based on moderate‑quality evidence. 9
• A fixed‑dose combination of acetaminophen + aspirin + caffeine has strong efficacy evidence – Level A recommendation. 8
• Patients must receive the maximum recommended dose of NSAIDs or acetaminophen before the therapy is deemed a failure – emphasizes dosing adequacy. 8

Critical Dosing Pitfalls

• Confirm that the maximum recommended daily dose is being used before declaring treatment failure – prevents premature escalation. 8
• Many patients achieve better relief by increasing the therapeutic dose rather than adding another medication – supports dose optimization first. 8

Second‑Line Options: CGRP Antagonists (Gepants)

• Oral CGRP antagonists are recommended for patients who do not tolerate or have an inadequate response to NSAIDs/acetaminophen alone – Level B evidence. 8

Third‑Line Options

• Dihydroergotamine (DHE) is effective when combination therapy with NSAIDs/acetaminophen fails – supported by Level B evidence. 8
• Lasmiditan is reserved for patients who have failed all other acute treatments – Level B recommendation. 8

Management of Severe Nausea/Vomiting

• Add an antiemetic (e.g., metoclopramide, prochlorperazine, domperidone) to any acute migraine regimen when nausea or vomiting is present – Level A recommendation. 8
• When vomiting is severe, consider non‑oral formulations of acute migraine medications – ensures drug delivery despite gastrointestinal intolerance. 8

Explicitly Contraindicated Medications

• Opioids are contraindicated for acute migraine because of dependence risk and medication‑overuse headache – strong recommendation against use. 8
• Butalbital‑containing products are also contraindicated for the same reasons – strong recommendation against use. 8

Timing of Treatment

• Initiate acute therapy as early as possible after headache onset to maximize efficacy – early treatment improves response across all medication classes. 8

Special Populations

• For patients of childbearing potential, discuss the risks and benefits of all acute migraine medications; acetaminophen remains the preferred first‑line agent during pregnancy and lactation – shared decision‑making emphasized. 8

Algorithmic Approach (Evidence‑Based Steps)

Common Pitfalls to Avoid

• Underdosing NSAIDs or acetaminophen before labeling treatment as failed reduces overall success rates – emphasizes proper dosing. 8
• Prescribing opioids or butalbital‑containing products worsens long‑term outcomes and creates dependence risk – strong contraindication. 8
• Assuming all agents within a class are interchangeable; trial different NSAIDs if the first choice is ineffective – supports individualized selection. 8
• Failing to add an antiemetic when nausea is present diminishes the efficacy of oral acute medications – highlights need for adjunct therapy. 8

Preventive Migraine Treatment Recommendations (American College of Physicians)

First‑Line Preventive Agents – Cost‑Sensitive Selection

• The American College of Physicians recommends prioritizing lower‑cost preventive medications when efficacy is comparable, favoring agents such as beta‑blockers, antiseizure drugs, and SNRIs for migraine prophylaxis. 10
• Beta‑blockers (e.g., propranolol 80–240 mg/day or metoprolol) are endorsed as effective first‑line options to reduce migraine frequency. 10
• Antiseizure medications (e.g., topiramate or divalproex sodium 500–1500 mg/day) are recommended as first‑line prophylaxis for migraine. 10
• The SNRI venlafaxine is listed among first‑line preventive agents for migraine. 10

Alternative First‑Line Options When Standard Agents Are Not Tolerated

• An ACE inhibitor (lisinopril) may be used as an alternative preventive medication for patients unable to tolerate standard agents. 10
• Angiotensin‑II receptor blockers (candesartan or telmisartan) are suggested as alternative first‑line options for migraine prophylaxis. 10

CGRP‑Targeted Therapies – Second‑Line Preventive Options

• When first‑line agents fail or are not tolerated, oral CGRP antagonists (gepants) such as atogepant or rimegepant are recommended. 10
• CGRP monoclonal antibodies (eptinezumab IV quarterly, erenumab, fremanezumab, or galcanezumab subcutaneously monthly or quarterly) are advised as second‑line preventive therapies, shown to reduce migraine days by 1–3 days per month versus placebo. 10

Cost Considerations

• The guideline emphasizes selecting less expensive, guideline‑recommended medications whenever clinically appropriate to lessen the overall treatment burden. 10

Acute Migraine Combination Therapy: Efficacy and Cost Considerations

Efficacy of Combination Therapy

Cost Considerations

Cost Table